Miriam Komaromy, MD

Professor, Medicine

Miriam Komaromy


Miriam Komaromy, MD is the Medical Director of the Grayken Center for Addiction at Boston Medical Center, and a Professor in the Division of General Internal Medicine, Department of Medicine, Chobanian and Avedisian School of Medicine. In her role at the Grayken Center she leads programs focused on expanding access to care and engagement with care for patients who have substance use disorders, particularly those from marginalized patient populations. Other areas of focus within the Grayken Center include:
–Research on how to make addiction treatment more appealing, effective, and equitable for Black patients
–Development of a new Grayken Addiction Nursing Fellowship and support for the Grayken Addiction Medicine Fellowships
–Leadership on adaptation of SUD treatment during the COVID pandemic, including BMC’s COVID Recuperation Unit for people who are COVID-infected and experiencing homelessness
–Implementation of a facility offering low-barrier housing and addiction-focused urgent care for people exiting from street encampments
–Policy and Advocacy focused on implementation of Overdose Prevention Centers, workforce development, modernizing methadone regulation, HIV prevention, and overdose prevention in newly housed individuals
–Development and Implementation of “Together for Hope: Boston Addiction Conference 2024”

Komaromy is mPI of a NIMH-funded clinical trial (along with mPI Dr. Kate Watkins of RAND corporation) that is evaluating the impact of the Collaborative Care model on outcomes of care for people who have co-occurring opioid use disorder plus PTSD or depression in 17 primary care clinics in New Mexico and California.

Komaromy serves as Vice President of AMERSA, the Association for Multidisciplinary Education and Research in Substance Use and Addiction, and also chairs the AMERSA Diversity Committee and the Climate the Task Force.

Prior to her role at BMC, Komaromy led the Extension for Healthcare Outcomes (ECHO) Institute’s programs for addiction and psychiatry. She has also served on the American Society of Addiction Medicine’s (ASAM’s) National Board of Directors (2017-2021) and In 2019 she received ASAM’s Educator of the Year award. She served as medical director for a state addiction treatment hospital in New Mexico and for Albuquerque Health Care for the Homeless.

Komaromy was previously a professor in the Department of Internal Medicine at the University of New Mexico. She received her medical degree from the University of California, San Francisco and completed her residency in internal medicine at UCSF/San Francisco General Hospital. She was a Robert Wood Johnson Clinical Scholar at the UCSF/Stanford program. She joined the UCSF faculty of Medicine after her training, and served as the residency director for the UCSF Primary Care Internal Medicine Residency program at San Francisco General Hospital. She is board certified in Internal Medicine by the American Board of Internal Medicine, and in Addiction Medicine by the American Board of Preventive Medicine.

Komaromy’s research has focused on health disparities and care for traditionally underserved populations; models of post-graduate medical education; and care for patients with substance use disorders and complex health conditions. In 2018, Komaromy received a Fulbright Scholar award from the US State Department, teaching about substance use disorders and medical education in Vietnam, Thailand, and Indonesia and studying treatment of opioid use disorder in Vietnam.


  • University of California, San Francisco, MD
  • St. John's College, BA


  • Published on 2/1/2024

    Mayer M, Mejia Urieta Y, Martinez LS, Komaromy M, Hughes U, Chatterjee A. Encampment Clearings And Transitional Housing: A Qualitative Analysis Of Resident Perspectives. Health Aff (Millwood). 2024 Feb; 43(2):218-225. PMID: 38315933.

    Read at: PubMed
  • Published on 10/26/2023

    Komaromy M, Stone A, Peterson A, Gott J, Koenig R, Taylor JL. Facilitating exit from encampments: combining low-barrier transitional housing with stabilizing treatment for substance related problems. Addict Sci Clin Pract. 2023 Oct 26; 18(1):66. PMID: 37884986.

    Read at: PubMed
  • Published on 8/3/2023

    Evans SK, Dopp A, Meredith LS, Ober AJ, Osilla KC, Komaromy M, Watkins KE. Findings from an Organizational Context Survey to Inform the Implementation of a Collaborative Care Study for Co-occurring Disorders. J Behav Health Serv Res. 2024 Jan; 51(1):4-21. PMID: 37537428.

    Read at: PubMed
  • Published on 5/8/2023

    Fox JM, Wason K, Beers D, Faulds M, Lincoln N, Tomanovich M, Gaden NW, Komaromy Md M. The Creation of an Addiction Nursing Fellowship Program for Registered Nurses: A Unique Approach to Enhancing the Addiction-Treatment Workforce. Subst Abus. 2023; 44(1):24-31. PMID: 37226903.

    Read at: PubMed
  • Published on 1/27/2023

    Murray-Krezan C, Dopp A, Tarhuni L, Carmody MD, Becker K, Anderson J, Komaromy M, Meredith LS, Watkins KE, Wagner K, Page K. Screening for opioid use disorder and co-occurring depression and post-traumatic stress disorder in primary care in New Mexico. Addict Sci Clin Pract. 2023 Jan 27; 18(1):6. PMID: 36707910.

    Read at: PubMed
  • Published on 4/8/2022

    Osilla KC, Dopp AR, Watkins KE, Ceballos V, Hurley B, Meredith LS, Leamon I, Jacobsohn V, Komaromy M. Collaboration Leading to Addiction Treatment and Recovery from Other Stresses (CLARO): process of adapting collaborative care for co-occurring opioid use and mental disorders. Addict Sci Clin Pract. 2022 Apr 08; 17(1):25. PMID: 35395811.

    Read at: PubMed
  • Published on 3/26/2022

    Qeadan F, Madden EF, Barbeau WA, Kroth PJ, Porucznik CA, English K, Komaromy M, Sulzer SH. Characteristics associated with the availability of therapeutic acupuncture in substance use disorder treatment facilities in the United States. J Addict Dis. 2023 Jan-Mar; 41(1):41-52. PMID: 35343390.

    Read at: PubMed
  • Published on 12/28/2021

    Laks J, Kehoe J, Farrell NM, Komaromy M, Kolodziej J, Walley AY, Taylor JL. Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule. Addict Sci Clin Pract. 2021 12 28; 16(1):73. PMID: 34961554.

    Read at: PubMed
  • Published on 11/1/2021

    Komaromy M, Tomanovich M, Taylor JL, Ruiz-Mercado G, Kimmel SD, Bagley SM, Saia KM, Costello E, Park TW, LaBelle C, Weinstein Z, Walley AY. Adaptation of a System of Treatment for Substance Use Disorders During the COVID-19 Pandemic. J Addict Med. 2021 Nov-Dec 01; 15(6):448-451. PMID: 33298750.

    Read at: PubMed
  • Published on 10/26/2021

    Qeadan F, Azagba S, Barbeau WA, Gu LY, Mensah NA, Komaromy M, English K, Madden EF. Associations between discrimination and substance use among college students in the United States from 2015 to 2019. Addict Behav. 2022 02; 125:107164. PMID: 34735979.

    Read at: PubMed

View 37 more publications: View full profile at BUMC

View all profiles